Alzamend Neuro CFO Lien Escalona resigns; COO David Katzoff appointed as new CFO

Alzamend Neuro, Inc.

Lien Escalona resigned as CFO effective August 1, 2022.
David J. Katzoff, previously COO, appointed CFO on August 5, 2022.
Katzoff joined Alzamend in Nov 2019 as SVP Operations, then COO from Dec 2020.
Katzoff also serves as SVP Finance of BitNile Holdings and CFO of Imperalis Holding Corp.
No employment agreement or compensation change for Katzoff at this time.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

David J. Katzoff

Chief Financial Officer

ALZN · Alzamend Neuro, Inc.

Effective: 2022-08-05
Filed: August 5, 2022, 7:59 PM ET

On August 5, 2022, the Company appointed David J. Katzoff, who has been serving as the Company’s Chief Operating Officer, as its new Chief Financial Officer.

Departed

Lien Escalona

Chief Financial Officer

ALZN · Alzamend Neuro, Inc.

Effective: 2022-08-01
Successor: David J. Katzoff
Filed: August 5, 2022, 7:59 PM ET

On August 1, 2022, Lien Escalona resigned as the Chief Financial Officer of Alzamend Neuro, Inc. (the “Company”), effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

David J. Katzoff was appointed as Chief Financial Officer at Alzamend Neuro, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On August 5, 2022, the Company appointed David J. Katzoff, who has been serving as the Company’s Chief Operating Officer, as its new Chief Financial Officer.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Lien Escalona resigned as Chief Financial Officer at Alzamend Neuro, Inc..

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

On August 1, 2022, Lien Escalona resigned as the Chief Financial Officer of Alzamend Neuro, Inc. (the “Company”), effective immediately.

View on SEC.gov

Alzamend Neuro, Inc. filing history →

Source: SEC EDGAR

accession 0001214659-22-009675

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.